Physiogenex will be presenting its innovative NASH animal models on January 10th-11th, 2020 at the NASH-TAG 2020 conference in Park City, UT, USA. Dr François Briand, our Director of Research and Development, will be presenting 2 posters during the 2-day conference...
PRECLINICAL CRO SERVICES FOR DRUGS TARGETING METABOLIC DISORDERS
Physiogenex provides preclinical in vivo and ex vivo CRO services with more than 15 years of expertise in evaluating drugs targeting metabolic disorders such as obesity, diabetes, NASH, fibrosis, diabetic nephropathy, cardiovascular complications, dyslipidemia and atherosclerosis.
We develop in-house and gold standard preclinical models in our cutting-edge facilities near Toulouse, France.
Along with our preclinical CRO services, we offer consulting services adapted to the specific needs of our clients. Our metabolic diseases experts offer their many years of experience in drug development to help you design and run efficient and cost-effective studies to shorten your product’s time to market.
STATE OF THE ART CRO FACILITIES
Physiogenex is located near Toulouse (France) in brand new facilities . Our technical platform is equipped with all appropriate devices to ensure high quality CRO services and reliable study results to our clients.
THEY TRUST US
We work with more than 100 biopharmaceutical, nutraceutical and agrifood companies
LATEST NEWS ABOUT PHYSIOGENEX
Physiogenex presented a poster on Monday, November 11th, 2019 at the AASLD Liver Meeting (November 8-12) in Boston, Massachusetts. Dr François Briand, our Director of Research and Development, attented the Poster Session held at the Hynes Convention Center and...
ENGLISH VERSION Brand new facilities for Physiogenex! In September, we celebrated the inauguration of our new laboratories near Toulouse, as well as our 15th anniversary. With more than 1000 m² dedicated to the research and development of new therapeutic strategies...